Asset Details
Do you wish to reserve the book?
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
Do you wish to request the book?
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
2010
Overview
Background:
The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen.
Method:
We report the outcome for a consecutive series of chemonaive patients with metastatic or locally advanced neuroendocrine tumours treated with a combination of 5-fluorouracil (500 mg m
−2
), cisplatin (70 mg m
−2
) and streptozocin (1000 mg m
−2
) (FCiSt) administered three weekly for up to six cycles. Patients were assessed for radiological response, toxicity and survival.
Results:
In the 79 patients assessable for response, treatment with FCiSt was associated with an overall response rate of 33% (38% for pancreatic primary sites and 25% for non-pancreatic primary sites). Stable disease occurred in a further 51%, with progression in 16%. The median time to progression was 9.1 months and median overall survival was 31.5 months. The most common grade 3–4 toxicity was neutropaenia (28% patients) but grade 3–4 infection was rare (7%). The most frequent non-haematological grade 3–4 toxicity was nausea and vomiting (17%). Prognostic factors included Ki-67, mitotic index, grade and chromogranin A, whereas response to chemotherapy was predicted by mitotic index, grade and
α
-fetoprotein.
Conclusions:
FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile. Grade and mitotic index are the best predictors of response.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - standards
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Cisplatin - administration & dosage
/ Female
/ Fluorouracil - administration & dosage
/ Fluorouracil - adverse effects
/ Fluorouracil - therapeutic use
/ Humans
/ Male
/ Neuroendocrine Tumors - drug therapy
/ Neuroendocrine Tumors - mortality
/ Oncology
/ Streptozocin - administration & dosage
/ Streptozocin - adverse effects
/ Streptozocin - therapeutic use
/ Tumors
